It has long been recognized that VEGF pathway inhibitors give only relatively short-lived benefit in preclinical models and cancer patients [29] and studies have suggested that this may be overcome by concomitant inhibition of additional pathways [5, 30, 31]. The gene discussed is VEGFA; the disease is cancer.